NC Medial Research Inc
This is an initial Phase1/2 dose-finding, double-blind, placebo-controlled, multi-center study to evaluate the safety and tolerability of NCS-01 in patients with acute ischemic stroke. All patients will be randomized within 24 hours of stroke onset. This study will be conducted in 2 stages.
Ischemic Stroke
NCS-01
Placebo
Phase 1
Phase 2
Study Type : | Interventional |
Estimated Enrollment : | 16 participants |
Masking: | Quadruple |
Primary Purpose: | Treatment |
Official Title: | A Phase 1/2, Dose-finding, Double-blind, Placebo-controlled, Multi-center Study to Evaluate the Safety, Tolerability of NCS-01 in Patients With Acute Ischemic Stroke |
Actual Study Start Date : | February 27, 2020 |
Estimated Primary Completion Date : | October 2023 |
Estimated Study Completion Date : | October 2024 |
Arm | Intervention/treatment |
---|---|
Experimental: NCS-01 human bone marrow derived cells |
Biological: NCS-01 |
Placebo Comparator: Placebo placebo |
Biological: Placebo |
Ages Eligible for Study: | 18 Years to 80 Years |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Want to participate in this study, select a site at your convenience, send yourself email to get contact details and prescreening steps.
Recruiting
The University of Texas
Houston, Texas, United States, 77030